Evidence Snapshot

Human immunodeficiency virus type 1 reverse transcriptase

CHEMBL247 SINGLE PROTEIN Human immunodeficiency virus 1

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T09:43:22Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 6:43 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL247

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human immunodeficiency virus type 1 reverse transcriptase as ChEMBL target CHEMBL247, mapped to UniProt Q72547. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Human immunodeficiency virus type 1 reverse transcriptase

SINGLE PROTEIN · Human immunodeficiency virus 1

As of 2026-09-13

ChEMBL target ID

CHEMBL247

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

Q72547

Reverse transcriptase/RNaseH

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Human immunodeficiency virus type 1 reverse transcriptase matters

As of 2026-09-13

Human immunodeficiency virus type 1 reverse transcriptase is reviewed as Reverse transcriptase/RNaseH (UniProt Q72547); Human immunodeficiency virus type 1 reverse transcriptase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block.; 31 linked drugs keep this evidence frame grounded.; the current evidence base includes 35 approved drugs, 8652 compounds, and 2087 assays, with lead potency reaching pChEMBL 10.8.

Protein context

Reverse transcriptase/RNaseH

Reverse transcriptase/RNaseH Sequence length is 566 aa.

Review this target as Human immunodeficiency virus type 1 reverse transcriptase, mapped to UniProt Q72547. ChEMBL maps the protein component as Reverse transcriptase/RNaseH. Sequence length is 566 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q72547 Protein

Disease context

HIV infection

Human immunodeficiency virus type 1 reverse transcriptase shows approved-linked disease relevance led by HIV infection. 5 more disease programs remain visible in the same review block. 31 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABACAVIR SULFATE, AMDOXOVIR, APRICITABINE.

Start review with HIV infection because it currently carries approved-linked support. Linked drugs include ABACAVIR SULFATE, AMDOXOVIR, APRICITABINE, ATEVIRDINE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 31 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 35 approved drugs, 8652 compounds, and 2087 assays for this target. The dominant activity type is IC50. CHEMBL3621607 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL3621607 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine

35 approved pChEMBL 10.8

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Human immunodeficiency virus type 1 reverse transcriptase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q72547, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why HIV infection is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8652

Total Compounds

2087

Total Assays

Approved Drugs

IC50: 10772.0, KI: 817.0, EC50: 1607.0, KD: 156.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL3621607	10.8	IC50	—
No preferred name CHEMBL3621611	10.7	IC50	—
No preferred name CHEMBL3621613	10.7	IC50	—
No preferred name CHEMBL3621604	10.7	IC50	—
No preferred name CHEMBL3621609	10.6	IC50	—